Comment #6 by Aviva Lev-Ari, PhD, RN
to Allan, M. Brandt’s article in NEJM, January 5, 2012
A Reader’s Guide to 200 Years of the New England Journal of Medicine
Circulating Endothelial Progenitor Cells Milestones in the research on Circulating Endothelial Progenitor Cells as diagnostic markers of cardiovascular risk have been reported in NEJM 2003 348:593– 600; (2005); Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes, NEJM, 353: 999-1007; Circulating Endothelial Progenitor Cells Correspondence http://www.nejm.org december 15, 2005; (2005) Correspondence to the Editor on Circulating Endothelial Progenitor Cells. NEJM, 353:24, 2613-2616; Werner, N & Nickenig, G. (2005b). Authors Reply to Correspondence to the Editor on Circulating Endothelial Progenitor Cells. NEJM, 353:24, 2613-2616. Based on that state of the art of research, I defined in 2006 an independent research study and carried out research on “Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk” An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPCs) as a Therapeutic Target for Pharmacological Therapy Design for Cardiovascular Risk Reduction: A New Multimarker Biomarker Discovery. I’ll attribute my increasing interest in Molecular Cardiology to above NEJM articles.
http://www.nejm.org/doi/full/10.1056/NEJMp1112812#t=comments
[…] http://pharmaceuticalintelligence.com/2012/07/12/circulating-endothelial-progenitor-cells-milestones… […]